Pharmaron Acquires Xceleron Inc.
Acquisition expands Pharmaron’s radiolabelled sciences capabilities
Pharmaron, a fully integrated contract research organization offering R&D services for the life science industry, today announced the acquisition of Xceleron Inc. Xceleron is a Maryland, US-based globally leading accelerator mass spectrometry (AMS) specialist for life sciences.
The AMS platform developed at Xceleron has unique sensitivity and features that allows identification and analysis of therapeutically and biologically relevant entities, including small molecules to large molecules at low concentrations. With this, Xceleron has supported regulatory filings for dozens of marketed drugs since 1998. The technology has been developed to support discovery of novel biomarkers and potentially new disease-modifying targets.
Xceleron’s use of microtracers and AMS detection technology complements Pharmaron’s existing platforms of radiolabelled compound manufacturing and radiolabelled metabolism operated in the United Kingdom. The combination of AMS and other established analytical technologies at Pharmaron supports early discovery, preclinical and clinical development. This acquisition is part of Pharmaron’s strategy to provide fully integrated, end-to-end R&D services.
Dr. Boliang Lou, Chairman and CEO of Pharmaron commented: “We are pleased to welcome another industry-leading R&D platform to the Pharmaron Group, once again demonstrating our commitment to becoming a global leader in drug R&D services. The addition of Xceleron develops and differentiates our capabilities in translational science and clinical development services, and further strengthens our ability to support our worldwide collaborators and partners with fully integrated pharmaceutical R&D services.”
Dr. Michael Butler, CEO, Xceleron commented: “With the support of our investors, the Xceleron team has worked diligently to create an analytical platform that is now accepted as a valuable component of the contemporary pharmaceutical development tool-box. We are excited to become a part of Pharmaron’s integrated drug research and development platform as it allows for new opportunities to serve our customers arising from the combination of our AMS technology with Pharmaron’s extensive and growing capabilities.”
Commercial details on the transaction are not being disclosed.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
See the theme worlds for related content
Topic World Spectroscopy
Investigation with spectroscopy gives us unique insights into the composition and structure of materials. From UV-Vis spectroscopy to infrared and Raman spectroscopy to fluorescence and atomic absorption spectroscopy, spectroscopy offers us a wide range of analytical techniques to precisely characterize substances. Immerse yourself in the fascinating world of spectroscopy!
Topic World Spectroscopy
Investigation with spectroscopy gives us unique insights into the composition and structure of materials. From UV-Vis spectroscopy to infrared and Raman spectroscopy to fluorescence and atomic absorption spectroscopy, spectroscopy offers us a wide range of analytical techniques to precisely characterize substances. Immerse yourself in the fascinating world of spectroscopy!
